Law360 (June 14, 2018, 12:03 PM EDT) -- An Illinois federal jury found for AbbVie Inc. on Thursday in a trial over claims its drug AndroGel caused a man’s deep vein thrombosis, handing the company a win in the fifth bellwether trial in the testosterone replacement therapy multidistrict litigation.
AbbVie is one of several makers of testosterone replacement products to face suits centralized in the MDL. (AP) After a few hours of deliberation, the jury rejected plaintiff Robert Rowley's claims that AndroGel was to blame for a clot he suffered in 2013 and that the company failed to adequately warn about the risk. It's the third complete defense verdict...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!